NEW YORK (GenomeWeb) – ATCC announced today that it has partnered with contract research organization BioAgilytix to develop new and custom cell-based assays for biopharmaceutical research and development.
Under the terms of the agreement, ATCC's tool and reagent development and storage services, including custom engineered cell lines and primary cells, will be sold alongside BioAgilytix's assays for biopharmaceutical drug testing, including ones for establishing drug potency, stability, safety, and efficacy. ATCC has also taken an undisclosed minority stake in BioAgilytix and will serve on its commercial advisory board.
Additional terms of the deal were not disclosed.
"The synergies created by combining our recognized expertise in cell line development, storage, management, and distribution with the impressive bioanalytical capabilities of BioAgilytix will help advance the progress of innovative therapies for patients in need around the world," ATCC CEO Raymond Cypess said in a statement.